StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Stock analysts at StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Friday. The brokerage set a “sell” rating on the stock.

CANF has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday, December 31st.

Can-Fite BioPharma Price Performance

NYSE CANF opened at $1.58 on Friday. Can-Fite BioPharma has a 1-year low of $1.29 and a 1-year high of $4.69. The firm has a market capitalization of $5.59 million, a P/E ratio of -0.88 and a beta of 1.36. The business’s 50-day simple moving average is $1.79 and its 200-day simple moving average is $2.31.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.